Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)39.86
  • Today's Change-0.315 / -0.78%
  • Shares traded69.01k
  • 1 Year change+50.47%
  • Beta--
Data delayed at least 20 minutes, as of Nov 14 2024 16:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,1097440
Total Receivables, Net3,5373,6443,398
Total Inventory2,7002,1242,006
Prepaid expenses135134121
Other current assets, total91----
Total current assets7,5725,9765,565
Property, plant & equipment, net1,8501,9041,933
Goodwill, net7,5897,4377,683
Intangibles, net1,5621,4541,581
Long term investments211519
Note receivable - long term201813
Other long term assets82207.00
Total assets19,43017,55717,542
LIABILITIES
Accounts payable1,5931,3571,173
Accrued expenses853665631
Notes payable/short-term debt000
Current portion long-term debt/capital leases323215191
Other current liabilities, total2,9295,6776,370
Total current liabilities5,6987,9148,365
Total long term debt4,230118120
Total debt4,553333311
Deferred income tax441437538
Minority interest9.001210.00
Other liabilities, total407328356
Total liabilities10,7858,8099,389
SHAREHOLDERS EQUITY
Common stock24----
Additional paid-in capital------
Retained earnings (accumulated deficit)8,6218,9208,257
Treasury stock - common(0.1)----
Unrealized gain (loss)------
Other equity, total0.10(172)(104)
Total equity8,6458,7488,153
Total liabilities & shareholders' equity19,43017,55717,542
Total common shares outstanding430431431
Treasury shares - common primary issue1.0700
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.